top of page

REVOLUTIONIZING
the Treatment of Advanced Parkinson’s Disease

Intrance Medical Systems, Inc., is a private, U.S.-based biopharmaceutical company focused on the development and commercialization of its lead clinical product for the treatment of advanced Parkinson’s disease in the U.S., Canada, South America, Japan and Taiwan. Intrance’s lead product, known as Lecigon® in the European market, is a fixed-dose combination treatment of levodopa, carbidopa and entacapone for enteral infusion in advanced Parkinson’s disease patients. The company is advancing its U.S. clinical development program in this target indication and has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA).

Intrance Medical-536810323_edited.jpg
Our History

We have a successful global history supported by a strong scientific foundation and proven clinical and commercial expertise.

Our Approach

Intrance’s novel approach has the potential to become a new standard of care allowing for continuous use and optimized treatment for advanced Parkinson’s disease.

Parkinson's Disease

Parkinson's disease (PD) affects nearly one million people in the United States. Most people living with PD will eventually progress to the advanced stage (APD).

bottom of page